强生公司已向欧洲药品管理局(EMA)提交了Tecvayli®▼ (Teclistamab)作为单药疗法的上市许可申请。该申请旨在寻求批准该药物用于治疗那些至少接受过一种前期疗法后仍出现复发或难治性的多发性骨髓瘤患者。
强生公司已向欧洲药品管理局(EMA)提交了Tecvayli®▼ (Teclistamab)作为单药疗法的上市许可申请。该申请旨在寻求批准该药物用于治疗那些至少接受过一种前期疗法后仍出现复发或难治性的多发性骨髓瘤患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.